Science Exchange Adds Allergan EVP & Chief R&D Officer David Nicholson to Its Board of Directors

PALO ALTO, Calif.--()--Science Exchange, Inc. announced today that C. David Nicholson, Ph.D., EVP and Chief R&D Officer at Allergan, has joined the Science Exchange Board of Directors. Dr. Nicholson’s experience includes over forty years in research and development in the pharmaceutical industry spanning senior leadership roles at Allergan, Bayer CropScience, Schering-Plough, Organon, and Merck.

"David Nicholson’s leadership, experience, and passion for research have made him one of the world’s most respected pharmaceutical R&D executives - he's an extraordinarily talented business development, operating, and research executive," said Elizabeth Iorns Ph.D., founder and CEO of Science Exchange. "We are fortunate to add David to Science Exchange’s Board of Directors during this exciting phase of the company’s growth."

"David is a seasoned R&D leader who brings an exceptional track record spanning more than 40 years in the pharmaceutical industry," said Casper de Clercq, Science Exchange Board Member and Partner at Norwest Venture Partners. "His deep experience working in R&D across the U.S., UK, Germany and the Netherlands, and his unique understanding of the global clinical and regulatory environment, will be invaluable as Science Exchange continues its rapid international expansion.”

Dr. Nicholson joined Allergan (then Actavis) as Senior Vice President, Global Brands R&D in August 2014. Previously Dr. Nicholson held senior leadership roles in R&D including serving as the Head of R&D at Bayer CropScience; Executive Vice President of R&D at Organon; and Senior Vice President Licensing and Knowledge Management at Merck.

"I am thrilled to join the Science Exchange Board of Directors," said Dr. Nicholson. "I've been following the company for some time now and am a true believer in the transformative platform it has developed for R&D companies. I admire the work that Elizabeth, Dan, and the talented Science Exchange management team have done over the past few years to speed up the process of R&D outsourcing. I look forward to joining the team and helping them further transform the outsourced R&D industry."

Dr. Nicholson also serves on the Board of Directors of Actinium Pharmaceuticals. He earned a Ph.D. in Pharmacology from University of Wales and a BSc in Pharmacology from Manchester University.

About Science Exchange

Science Exchange is the world's Leading Marketplace for Outsourced R&D™, providing large R&D organizations with the fastest path from discovery through development and commercialization. Science Exchange includes an efficient source-to-secure platform for ordering 6,000+ services from a network of more than 2,500 qualified outsourced research providers, all with pre-established contracts in place that protect client intellectual property and confidentiality. The platform increases access to innovation and improves productivity, freeing scientists from administrative tasks and delays associated with sourcing, establishing and managing service provider contracts. Additionally, the Science Exchange enterprise program enables large R&D organizations to consolidate research outsourcing spend into a single strategic relationship, driving efficiency, improving transparency and oversight, and delivering cost savings. Since being founded in 2011, Science Exchange has raised more than $58 million from Norwest Venture Partners, Maverick Capital Ventures, Union Square Ventures, Collaborative Fund, Index Ventures, OATV, the YC Continuity Fund, and others. For more information, visit www.ScienceExchange.com. Follow the company on Twitter @ScienceExchange.

Contacts

Science Exchange
Gursatya "Guru" Singh
Director of Scientific Content
marketing@scienceexchange.com

Contacts

Science Exchange
Gursatya "Guru" Singh
Director of Scientific Content
marketing@scienceexchange.com